APA (7th ed.) Citation

JJ, M., JS, F., CH, L., T, L., A, M., HR, L., . . . CC, L. (2021). Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer. Nature communications, 12(1), 723. https://doi.org/10.1038/s41467-021-20962-6

Chicago Style (17th ed.) Citation

JJ, McGuire, Frieling JS, Lo CH, Li T, Muhammad A, Lawrence HR, Lawrence NJ, Cook LM, and Lynch CC. "Mesenchymal Stem Cell-derived Interleukin-28 Drives the Selection of Apoptosis Resistant Bone Metastatic Prostate Cancer." Nature Communications 12, no. 1 (2021): 723. https://doi.org/10.1038/s41467-021-20962-6.

MLA (9th ed.) Citation

JJ, McGuire, et al. "Mesenchymal Stem Cell-derived Interleukin-28 Drives the Selection of Apoptosis Resistant Bone Metastatic Prostate Cancer." Nature Communications, vol. 12, no. 1, 2021, p. 723, https://doi.org/10.1038/s41467-021-20962-6.